## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 2.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.48)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. 357,638 Shares in GE HealthCare Technologies Inc. $GEHC Acquired by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T123511 | Bullish | Relevance: 100%
- Wedge Capital Management L L P NC has acquired a new stake of 357,638 shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC), valued at approximately $26.9 million. This purchase represents about 0.08% of the company's shares. Other institutional investors like Vanguard Group Inc. and Dodge & Cox also increased their holdings in GE HealthCare, indicating strong institutional interest.

**2. GE HealthCare Technologies Inc. $GEHC Stock Position Lowered by Texas Permanent School Fund Corp**
- Source: MarketBeat | 20251221T103757 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 34.8% in Q2, selling 17,157 shares and retaining 32,207 shares valued at approximately $2.39 million. Despite this, analyst sentiment remains mixed-to-positive with a "Moderate Buy" consensus rating and an average price target of $87.09, while the company recently exceeded EPS estimates and provided positive FY2025 guidance. GE HealthCare, with a market cap of $37.8 billion and a P/E of 17.1, also announced a quarterly dividend.

**3. Morgan Stanley Raises iRhythm (IRTC) PT on MedTech Recovery Outlook**
- Source: Yahoo Finance UK | 20251222T145613 | Somewhat-Bullish | Relevance: 64%
- Morgan Stanley increased its price target for iRhythm Technologies (IRTC) from $195 to $205, maintaining an Overweight rating, based on a positive outlook for the MedTech industry. The industry is expected to benefit from new product cycles, supportive hospital spending, and attractive valuations. Additionally, new data shows iRhythm's Zio long-term continuous ECG monitoring system performs consistently across diverse patient populations.

**4. Is Boston Scientific (BSX) One of the Best Healthcare AI Stocks to Buy Now?**
- Source: Finviz | 20251223T010913 | Neutral | Relevance: 61%
- TD Cowen has reaffirmed a Buy rating on Boston Scientific (BSX), naming it their "Best Idea for 2026" due to its strong growth story in the medical devices sector. The firm expects over 10% organic sales growth annually and double-digit EPS growth, driven by key products like Farapulse and Watchman. Boston Scientific also leverages AI in its medical devices to enhance imaging, predictive analytics, and remote monitoring.

**5. Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251222T110830 | Neutral | Relevance: 61%
- Seilern Investment Management Ltd reduced its stake in Edwards Lifesciences Corporation by 14.8%, selling 183,101 shares and now holding 1,055,774 shares valued at approximately $82.1 million. The article notes that insider selling has occurred this quarter, while institutional investors own a significant portion of the stock. Analyst sentiment remains bullish-to-neutral with a "Moderate Buy" consensus rating and a $93.95 target price, following Edwards Lifesciences' recent positive quarterly results and FY2025 EPS guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.48 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.0B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.48 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.6% to -0.2% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.25% (CS: 54) | Neutral |
| RSI_14 | 57.5 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.32
- **Stop Loss:** $79.48 (4.6% risk)
- **Target:** $87.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 312
- **Position Value:** $25,995.84
- **Portfolio %:** 26.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*